This is a preview of subscription content, log in via an institution to check access.
Notes
funded by Novartis Pharma Schweiz
Reference
Moradi-Lakeh M, et al. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland. Advances in Therapy : 22 May 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01767-x
Rights and permissions
About this article
Cite this article
Tisagenlecleucel cost effective in two patient populations in the Switzerland setting. PharmacoEcon Outcomes News 879, 27 (2021). https://doi.org/10.1007/s40274-021-7750-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7750-8